Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: DNDN - Dendreon Corp.

No earlier versions found for this Subject.

Return to DNDN - Dendreon Corp.

IPO soon....some Immunex people driving the ship

Dendreon Corporation, based in Seattle, Washington, discovers and develops immunologically based therapeutic products for the treatment of cancer. Dendreon is focused on the development of therapeutic vaccines for the treatment of cancer using antigen engineering and proprietary cell separation technologies. The Company is conducting a Phase III clinical trial for Provenge(TM), its prostate cancer vaccine, and Phase II clinical trials for its multiple myeloma vaccine.